Anika Therapeutics (NASDAQ:ANIK - Get Free Report)'s stock had its "sell (e+)" rating reissued by investment analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.
Separately, Barrington Research reaffirmed an "outperform" rating and set a $15.00 target price on shares of Anika Therapeutics in a research note on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.00.
Get Our Latest Report on ANIK
Anika Therapeutics Trading Up 1.7%
ANIK traded up $0.15 on Wednesday, hitting $9.24. 55,955 shares of the company's stock were exchanged, compared to its average volume of 91,397. Anika Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $25.65. The firm has a 50-day moving average price of $8.87 and a 200-day moving average price of $11.22. The stock has a market cap of $133.24 million, a price-to-earnings ratio of -2.23 and a beta of 0.62.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in Anika Therapeutics by 4,714.3% in the first quarter. GAMMA Investing LLC now owns 6,403 shares of the biotechnology company's stock valued at $96,000 after buying an additional 6,270 shares during the last quarter. Cetera Investment Advisers acquired a new position in Anika Therapeutics in the first quarter valued at about $152,000. AQR Capital Management LLC acquired a new position in Anika Therapeutics in the first quarter valued at about $181,000. Atria Investments Inc lifted its position in Anika Therapeutics by 19.3% in the second quarter. Atria Investments Inc now owns 13,096 shares of the biotechnology company's stock valued at $139,000 after buying an additional 2,118 shares during the last quarter. Finally, Man Group plc acquired a new position in Anika Therapeutics in the second quarter valued at about $140,000. Institutional investors and hedge funds own 91.53% of the company's stock.
About Anika Therapeutics
(
Get Free Report)
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anika Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anika Therapeutics wasn't on the list.
While Anika Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
